<DOC>
	<DOCNO>NCT00003433</DOCNO>
	<brief_summary>RATIONALE : Immunotherapy use CEA-treated white blood cell may help person 's body build immune response kill tumor cell . PURPOSE : Phase I/II trial study effectiveness immunotherapy CEA-treated white blood cell treat patient resect liver metastasis colon cancer .</brief_summary>
	<brief_title>Immunotherapy Treating Patients With Resected Liver Metastases From Colon Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine cellular immune response carcinoembryonic antigen pulse dendritic cell patient adenocarcinoma colon metastatic liver . - Evaluate overall recurrence free survival patient population . OUTLINE : Patients undergo leukapheresis 4.5 hour collect dendritic cell . The separated dendritic cell pulse carcinoembryonic antigen ( CEA ) RNA . Patients receive CEA RNA pulse dendritic cell intravenously every 2 week total 4 dos . Patients undergo second leukapheresis 2 week last dendritic cell infusion obtain specimens immunologic test . Patients extra dos dendritic cell available may receive additional dos CEA RNA pulse dendritic cell every 2 month absence unacceptable toxicity . Patients follow week 12 , 24 , 36 , 48 , every 6 month thereafter . PROJECTED ACCRUAL : A total 22 patient accrue study 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon metastatic liver express carcinoembryonic antigen ( CEA ) resection curative intent At least 50 % tumor cell must stain positive CEA least moderate intensity No gross residual disease surgery PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Greater 6 month Hematopoietic : Absolute neutrophil count least 1000/mm 3 Hemoglobin least 9 g/dL Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL No chronic acute hepatic disease Renal : Creatinine le 2.5 mg/dL Cardiovascular : No chronic acute cardiac disease ( New York Heart Association class III IV ) Pulmonary : No chronic acute pulmonary illness asthma chronic obstructive pulmonary disease Other : Not pregnant nursing No prior concurrent malignancy except nonmelanoma skin cancer control superficial bladder cancer within past 5 year No history autoimmune disease inflammatory bowel disease , systemic lupus erythematosus , ankylose spondylitis , scleroderma , multiple sclerosis No active acute chronic infection urinary tract infection , HIV , viral hepatitis No active infectious enteritis eosinophilic enteritis PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No concurrent chemotherapy At least 6 week since prior chemotherapy Endocrine therapy : No concurrent steroid therapy ( immunosuppressive ) At least 6 week since prior steroid therapy Radiotherapy : No concurrent radiotherapy At least 6 week since prior radiotherapy Surgery : Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>